Bioinformatics Market worth $34.41 billion by 2031
The report "Bioinformatics Market by Offering [Software (Genomics, Multiomics, Proteomics), Services (Analysis, Sequencing)], Function (Variant & Structural Analysis), Use Case (Drug Discovery, Biomarker), End User (Pharma & Biotech, CROs) - Global Forecast to 2031", is projected to grow from USD 18.63 billion in 2026 and to reach USD 34.41 billion by 2031, at a Compound Annual Growth Rate (CAGR) of 13.1% during the forecast period.
Browse 220 market data Tables and 36 Figures spread through 226 Pages and in-depth TOC on "Bioinformatics Market by Offering [Software (Genomics, Multiomics, Proteomics), Services (Analysis, Sequencing)], Function (Variant & Structural Analysis), Use Case (Drug Discovery, Biomarker), End User (Pharma & Biotech, CROs) - Global Forecast to 2031"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/bioinformatics-39.html
The bioinformatics market is driven by several key factors. One of the most significant drivers is the growing integration of artificial intelligence (AI), machine learning (ML), and cloud computing into bioinformatics workflows. These technologies enhance the speed and accuracy of genomic data analysis, enable predictive modeling, improve variant interpretation, and support the identification of novel therapeutic targets. AI-powered bioinformatics platforms are increasingly used to automate data analysis, reduce computational time, and improve research productivity. In addition, cloud-based bioinformatics solutions enable secure storage, scalable computing, and real-time collaboration among researchers, healthcare providers, and pharmaceutical companies across locations, reducing the need for expensive on-premises infrastructure.
Multi-omic integration segment to register fastest growth in bioinformatics market
By function, multi-omics integration is expected to register the fastest growth in the bioinformatics market. This strong growth is mainly due to the growing use of omics-based methods in the areas of precision medicine, biomarker discovery, and drug discovery. With the increasing availability of biological data from next-generation sequencing and other molecular profiling techniques such as proteomics and metabolomics, there is a need for advanced bioinformatics tools for integrating and analyzing multidimensional data. Also, the increasing use of artificial intelligence (AI) and machine learning (ML) in multi-omics research is enabling better data integration, modeling, and analytics. Research in cancer genomics, rare disease research, immunology, and systems biology is anticipated to drive adoption of multi-omics data integration solutions.
Pharmaceutical & biotechnology companies held largest share of bioinformatics market in 2025
By end user, the bioinformatics market is divided into pharmaceutical and biotechnology companies, academic and research institutes, hospitals and clinical diagnostic laboratories, contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs), government and public health organizations, and other end users. Pharmaceutical and biotechnology companies hold the largest share of the bioinformatics market in 2025. Growth in this segment is driven by the increasing use of bioinformatics in drug discovery and development, including target validation, molecular modeling, and lead optimization. The rising adoption of next-generation sequencing (NGS) technologies and multi-omics approaches has generated significant demand for advanced bioinformatics platforms to analyze complex biological data. Additionally, the growing focus on precision medicine, personalized therapies, and biomarker-based drug development is encouraging pharmaceutical companies to integrate bioinformatics into research workflows. Increasing investments in artificial intelligence (AI), machine learning (ML), and computational biology are further enhancing capabilities in predictive analytics, virtual screening, and therapeutic discovery.
Asia Pacific to register highest growth rate during forecast period
The bioinformatics market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Asia Pacific is expected to register the highest growth during the forecast period. Growth in the region is driven by rising adoption of next-generation sequencing (NGS) technologies, increasing research in molecular biology, and growing demand for precision medicine and personalized healthcare. The region's large and diverse patient population, along with the rising prevalence of chronic diseases such as cancer, diabetes, and genetic disorders, is creating demand for advanced genomic analysis and bioinformatics-based diagnostic solutions. Additionally, improving healthcare infrastructure, expanding biotechnology and pharmaceutical industries, and increasing government initiatives supporting genomics and digital healthcare are contributing to market growth. Countries such as China, India, Japan, South Korea, and Singapore are investing significantly in genomic research, artificial intelligence, and healthcare technology platforms.
The major players operating in this market are Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Revvity, Inc. (US), Eurofins Scientific (Luxembourg), BGI Genomics (China), Waters Corporation (US), DNAnexus, Inc. (US), Oxford Nanopore Technologies plc. (UK), 10x Genomics (US), PacBio (US), Dotmatics (US), and SOPHiA GENETICS (US).
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Bioinformatics Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
